Residency · Residency · Neurology
Status Epilepticus: Recognition and Stepwise Management
Overview
Status epilepticus (SE) is a neurological emergency defined as continuous seizure activity lasting 5 minutes or longer, or two or more seizures without full recovery of consciousness between them. Convulsive SE carries a mortality of 15-20%, and that risk increases with every minute of treatment delay. Nonconvulsive SE (NCSE) is frequently underrecognized and requires EEG for diagnosis. Successful management depends on a structured, time-based protocol with escalating therapies.
Definitions and Classification
Operational Definitions (ILAE 2015)
Convulsive SE (CSE) is defined as continuous generalized tonic-clonic seizure activity lasting 5 minutes or more. Nonconvulsive SE (NCSE) refers to electrographic seizure activity on EEG without prominent motor manifestations, presenting clinically as altered mental status, confusion, or subtle motor signs such as eye deviation, nystagmoid movements, or facial twitching. Refractory SE (RSE) persists despite adequate doses of both first-line benzodiazepines and a second-line agent. Super-refractory SE (SRSE) is defined as seizure activity that persists for 24 hours or more after the onset of anesthetic therapy, or that recurs during attempts to wean anesthetics.
Types of SE
Generalized convulsive SE is the most immediately dangerous form and requires the most aggressive immediate treatment. Focal motor SE, also called epilepsia partialis continua, manifests as a continuous focal motor seizure that may not impair consciousness. Nonconvulsive SE with coma involves continuous EEG seizure activity in obtunded or comatose patients. Absence SE is a non-motor generalized form presenting with prolonged confusion and generalized spike-wave on EEG; it is less dangerous but still requires treatment.
Etiology
Acute symptomatic causes include CNS infection, stroke, traumatic brain injury, metabolic derangements (hypoglycemia, hyponatremia, hypocalcemia, uremia), drug toxicity or withdrawal (particularly alcohol and benzodiazepines), and autoimmune encephalitis. In patients with established epilepsy, ASM nonadherence is the most common precipitant, followed by subtherapeutic drug levels and intercurrent illness. Remote symptomatic causes involve patients with prior brain injury and chronic epilepsy who present in SE. Approximately 10-20% of cases are cryptogenic or of unknown cause. Certain etiologies have specific treatments: hypoglycemia requires dextrose, pyridoxine deficiency in neonates requires IV vitamin B6, eclampsia requires magnesium, and isoniazid toxicity requires pyridoxine.
Stepwise Management Protocol
Phase 1: Stabilization (0-5 minutes)
The initial approach follows ABCs: secure the airway, ensure adequate breathing and circulation. The patient should be positioned to prevent injury, the airway suctioned, and nothing should be inserted into the mouth. IV access is obtained; if this is not possible, IM or intranasal routes are prepared. Point-of-care glucose measurement is essential; if the patient is hypoglycemic, 50 mL of 50% dextrose IV is administered (with thiamine 100 mg IV if the patient is malnourished or has a history of alcohol use). Laboratory studies including BMP, CBC, LFTs, ASM levels, toxicology screen, and lactate are drawn. The seizure duration is timed from this point.
| Phase | Time | Treatment | Dose |
|---|---|---|---|
| 1. Stabilization | 0–5 min | ABCs, glucose check, IV access, labs | Dextrose 50 mL of D50 if hypoglycemic |
| 2. First-line | 5–20 min | Lorazepam IV | 0.1 mg/kg (max 4 mg), repeat x1 |
| OR Midazolam IM | 10 mg (>40 kg) | ||
| OR Diazepam IV | 0.15–0.2 mg/kg (max 10 mg) | ||
| 3. Second-line | 20–40 min | Fosphenytoin IV | 20 mg PE/kg |
| OR Levetiracetam IV | 60 mg/kg (max 4500 mg) | ||
| OR Valproate IV | 40 mg/kg (max 3000 mg) | ||
| 4. Refractory | 40–60 min | Second agent trial or Lacosamide 400 mg IV | — |
| 5. Anesthetic | 60+ min | Midazolam infusion | 0.2 mg/kg load → 0.1–2 mg/kg/hr |
| OR Propofol | 2–3 mg/kg load → 30–200 mcg/kg/min | ||
| OR Pentobarbital | 5–15 mg/kg load → 0.5–5 mg/kg/hr |
Phase 2: First-Line Therapy -- Benzodiazepines (5-20 minutes)
The goal is to abort the seizure as rapidly as possible. IV lorazepam at 0.1 mg/kg (maximum 4 mg) is the preferred IV agent because it has a longer CNS duration than diazepam; it may be repeated once in 5-10 minutes. IM midazolam at 10 mg for patients over 40 kg is preferred in the prehospital setting and when IV access is unavailable, with onset in 3-5 minutes. IV diazepam at 0.15-0.2 mg/kg (maximum 10 mg) has rapid onset but short CNS duration due to redistribution and should be followed by a longer-acting agent. Rectal diazepam at 0.2-0.5 mg/kg is used in pediatric and prehospital settings. Intranasal midazolam is another alternative when IV access is unavailable.
The RAMPART trial (2012) compared IM midazolam (10 mg) against IV lorazepam (4 mg) for prehospital convulsive SE and found that IM midazolam was non-inferior and numerically superior due to faster time to administration despite slower absorption. This established IM midazolam as the standard prehospital first-line agent.
Phase 3: Second-Line Therapy -- Urgent Control (20-40 minutes)
If seizures persist after two adequate doses of benzodiazepine, one second-line agent is chosen and administered as an IV loading dose. The ESETT trial (2019) randomized patients with benzodiazepine-refractory SE to fosphenytoin (20 mg PE/kg), levetiracetam (60 mg/kg, maximum 4500 mg), or valproate (40 mg/kg, maximum 3000 mg). All three agents were equally effective, achieving seizure cessation in approximately 45-50% of patients at 60 minutes, and all three were equally safe with no significant differences in adverse events. The choice among them therefore depends on patient-specific factors.
Fosphenytoin should be avoided in patients with cardiac disease (risk of hypotension, bradycardia, and arrhythmia), known allergy, or hepatic porphyria, and requires cardiac monitoring. Levetiracetam has minimal drug interactions, no hemodynamic effects, and no hepatotoxicity, making it useful when the other agents are contraindicated. Valproate should be avoided in liver disease, mitochondrial disease (risk of fatal hepatotoxicity), pregnancy, thrombocytopenia, and pancreatitis; it has broad-spectrum efficacy and is particularly useful for generalized SE.
Phase 4: Refractory SE (40-60 minutes)
When seizures persist despite a benzodiazepine plus one second-line agent, options before proceeding to anesthetics include trying a second second-line agent (for example, adding levetiracetam or valproate if fosphenytoin was given first) or administering lacosamide 400 mg IV (off-label but increasingly used due to rapid infusion and minimal hemodynamic effects). If seizures continue despite these measures, continuous IV anesthetic agents are required.
Phase 5: Anesthetic Therapy for Refractory/Super-Refractory SE
This phase requires intubation, mechanical ventilation, and continuous EEG monitoring. Midazolam infusion (loading dose 0.2 mg/kg, then 0.1-2 mg/kg/hr) offers shorter recovery time and less hypotension but is prone to tachyphylaxis. Propofol (loading dose 2-3 mg/kg, then 30-200 mcg/kg/min) provides rapid onset and offset but carries the risk of propofol infusion syndrome (PRIS) with prolonged high-dose use, manifesting as metabolic acidosis, rhabdomyolysis, cardiac failure, and hypertriglyceridemia; CK and triglycerides must be monitored. Pentobarbital (loading dose 5-15 mg/kg, then 0.5-5 mg/kg/hr) is the most potent option but causes the most hemodynamic instability and is reserved for when midazolam and propofol fail. The EEG target is seizure suppression (preferred) or burst suppression, maintained for 24-48 hours before slow weaning with continuous EEG surveillance for seizure recurrence.
Super-Refractory SE
When seizures persist 24 hours or more after anesthetic initiation, additional options include ketamine infusion (an NMDA antagonist that may work when GABAergic agents fail due to receptor internalization), immunotherapy (IVIG, corticosteroids, plasmapheresis) when an autoimmune etiology is suspected, the ketogenic diet (evidence limited to case series), electroconvulsive therapy (case reports), hypothermia (limited evidence), and allopregnanolone/brexanolone (a neurosteroid with emerging data).
Receptor Trafficking in Prolonged SE
During prolonged seizures, GABA-A receptors are internalized (endocytosed) from the synaptic membrane, progressively reducing benzodiazepine efficacy over time. Simultaneously, NMDA receptors are trafficked to the synaptic membrane, increasing excitotoxicity. This receptor trafficking explains why benzodiazepines become less effective with treatment delay and why NMDA antagonists like ketamine may be beneficial in late-stage refractory SE. It also underscores the critical importance of early, aggressive benzodiazepine treatment before receptor internalization occurs.
Nonconvulsive Status Epilepticus (NCSE)
NCSE should be suspected in any patient with unexplained altered mental status, particularly after convulsive SE (known as "subtle SE"), in ICU patients, after cardiac arrest, or in patients with known epilepsy who fail to return to baseline. Clinical signs may be minimal, limited to eye deviation, nystagmus, or subtle facial twitching. Diagnosis requires EEG. The Salzburg criteria define NCSE as repetitive epileptiform discharges above 2.5 Hz for 10 seconds or more, or discharges below 2.5 Hz with spatial or temporal evolution, fluctuation, or improvement with an IV benzodiazepine trial. Treatment follows the same stepwise approach as convulsive SE, though the threshold for escalating to anesthetic therapy is debated given the need to balance the risks of aggressive treatment against the risks of ongoing seizure activity.
<image>A time-based treatment protocol infographic for status epilepticus. The horizontal axis represents time from seizure onset (0 to 60+ minutes). At 0-5 minutes: stabilization phase (ABCs, glucose, labs, timing). At 5-20 minutes: first-line benzodiazepines (lorazepam IV or midazolam IM, with RAMPART trial result noted). At 20-40 minutes: second-line agents (fosphenytoin, levetiracetam, or valproate with ESETT trial equivalence noted). At 40-60 minutes: refractory SE (second agent trial, lacosamide). At 60+ minutes: anesthetic therapy (midazolam, propofol, or pentobarbital infusion with intubation and cEEG). Each phase includes drug doses, routes, and decision points. A color gradient from green to red indicates increasing urgency and mortality risk with each escalation.</image>
<image>A diagram illustrating GABA-A receptor trafficking during prolonged status epilepticus. Panel 1 shows the normal synapse with abundant surface GABA-A receptors responding to benzodiazepines (high efficacy). Panel 2 shows the synapse after 30 minutes of seizures with GABA-A receptors internalized into endosomes (reduced benzodiazepine efficacy) and NMDA receptors increased at the surface (enhanced excitotoxicity). An arrow shows the clinical implication: early benzodiazepine treatment is critical because efficacy declines with time, and NMDA antagonists (ketamine) may be beneficial in refractory stages. A graph overlay shows benzodiazepine efficacy declining and seizure duration increasing over time.</image>
Clinical Pearls
Every minute of delayed benzodiazepine treatment reduces the probability of seizure termination -- "time is brain" applies to status epilepticus just as much as to stroke. IM midazolam is superior to IV lorazepam in the prehospital setting because it can be administered faster, as demonstrated by the RAMPART trial. The ESETT trial established that fosphenytoin, levetiracetam, and valproate are equally effective as second-line agents, so the choice should be based on patient-specific contraindications. After convulsive SE stops, clinicians should always assume NCSE may be continuing and obtain an urgent EEG, especially if the patient does not return to baseline within 20-30 minutes. GABA-A receptor internalization during prolonged seizures provides the mechanistic explanation for the diminishing efficacy of benzodiazepines with treatment delay. Propofol infusion syndrome is a life-threatening complication of prolonged, high-dose propofol use, requiring monitoring of CK, triglycerides, and lactate. Always check for reversible causes including glucose, sodium, calcium, ASM levels, and toxicology, and consider autoimmune encephalitis in cases of new-onset refractory SE (NORSE).
References
- Silbergleit R, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus (RAMPART). N Engl J Med. 2012;366(7):591-600.
- Kapur J, et al. Randomized trial of three anticonvulsant medications for status epilepticus (ESETT). N Engl J Med. 2019;381(22):2103-2113.
- Brophy GM, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3-23.
- Trinka E, et al. A definition and classification of status epilepticus -- report of the ILAE Task Force. Epilepsia. 2015;56(10):1515-1523.
- Hirsch LJ, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE). Epilepsia. 2018;59(4):739-744.
